Skip to main content
PMC home page
British Journal of Cancer logoLink to British Journal of Cancer
. 1999 Apr;80(1-2):269–272. doi: 10.1038/sj.bjc.6690350

Long-term survival after epirubicin, cisplatin and fluorouracil for gastric cancer: results of a randomized trial

J S Waters 1, A Norman 1, D Cunningham 1, J H Scarffe 2, A Webb 1, P Harper 3, J K Joffe 4, M Mackean 5, J Mansi 6, M Leahy 2, A Hill 1, J Oates 1, S Rao 1, M Nicolson 1, T Hickish 1
PMCID: PMC2363002  PMID: 10390007

Abstract

We report the final results of a prospectively randomized study that compared the combination of epirubicin, cisplatin and protracted venous infusion fluorouracil (5-FU) (ECF regimen) with the standard combination of 5-FU, doxorubicin and methotrexate (FAMTX) in previously untreated patients with advanced oesophagogastric cancer. Between 1992 and 1995, 274 patients with adenocarcinoma or undifferentiated carcinoma were randomized from eight oncology centres in the UK and analysed for response and survival. The overall response rate was 46% (95% confidence interval (CI), 37–55%) with ECF, and 21% (95% CI, 13–28%) with FAMTX (P = 0.00003). The median survival was 8.7 months with ECF and 6.1 months with FAMTX (P = 0.0005). The 2-year survival rates were 14% (95% CI, 8–20%) for the ECF arm, and 5% (95% CI, 2–10%) for the FAMTX arm (P = 0.03). Histologically complete surgical resection following chemotherapy was achieved in ten patients in the ECF arm (three pathological complete responses to chemotherapy) and three patients in the FAMTX arm (no pathological complete responses). The ECF regimen resulted in a response and survival advantage compared with FAMTX chemotherapy. The probability of long-term survival following surgical resection of residual disease is increased by this treatment. The high response rates seen with ECF support its use in the neoadjuvant setting. © 1999 Cancer Research Campaign

Keywords: cancer, chemotherapy, ECF, FAMTX, gastric, oesophagogastric

Full Text

The Full Text of this article is available as a PDF (72.5 KB).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Allum W. H., Powell D. J., McConkey C. C., Fielding J. W. Gastric cancer: a 25-year review. Br J Surg. 1989 Jun;76(6):535–540. doi: 10.1002/bjs.1800760604. [DOI] [PubMed] [Google Scholar]
  2. Beer M., Cocconi G., Ceci G., Varini M., Cavalli F. A phase II study of cisplatin in advanced gastric cancer. Eur J Cancer Clin Oncol. 1983 Jun;19(6):717–720. doi: 10.1016/0277-5379(83)90003-2. [DOI] [PubMed] [Google Scholar]
  3. Cascinu S., Labianca R., Alessandroni P., Marcellini M., Silva R. R., Pancera G., Testa E., Martignoni G., Barni S., Frontini L. Intensive weekly chemotherapy for advanced gastric cancer using fluorouracil, cisplatin, epi-doxorubicin, 6S-leucovorin, glutathione, and filgrastim: a report from the Italian Group for the Study of Digestive Tract Cancer. J Clin Oncol. 1997 Nov;15(11):3313–3319. doi: 10.1200/JCO.1997.15.11.3313. [DOI] [PubMed] [Google Scholar]
  4. Cersosimo R. J., Hong W. K. Epirubicin: a review of the pharmacology, clinical activity, and adverse effects of an adriamycin analogue. J Clin Oncol. 1986 Mar;4(3):425–439. doi: 10.1200/JCO.1986.4.3.425. [DOI] [PubMed] [Google Scholar]
  5. Cocconi G., Bella M., Zironi S., Algeri R., Di Costanzo F., De Lisi V., Luppi G., Mazzocchi B., Rodinò C., Soldani M. Fluorouracil, doxorubicin, and mitomycin combination versus PELF chemotherapy in advanced gastric cancer: a prospective randomized trial of the Italian Oncology Group for Clinical Research. J Clin Oncol. 1994 Dec;12(12):2687–2693. doi: 10.1200/JCO.1994.12.12.2687. [DOI] [PubMed] [Google Scholar]
  6. Etienne M. C., Bernard S., Fischel J. L., Formento P., Gioanni J., Santini J., Demard F., Schneider M., Milano G. Dose reduction without loss of efficacy for 5-fluorouracil and cisplatin combined with folinic acid. In vitro study on human head and neck carcinoma cell lines. Br J Cancer. 1991 Mar;63(3):372–377. doi: 10.1038/bjc.1991.88. [DOI] [PMC free article] [PubMed] [Google Scholar]
  7. Findlay M., Cunningham D., Norman A., Mansi J., Nicolson M., Hickish T., Nicolson V., Nash A., Sacks N., Ford H. A phase II study in advanced gastro-esophageal cancer using epirubicin and cisplatin in combination with continuous infusion 5-fluorouracil (ECF). Ann Oncol. 1994 Sep;5(7):609–616. doi: 10.1093/oxfordjournals.annonc.a058932. [DOI] [PubMed] [Google Scholar]
  8. Glimelius B., Ekström K., Hoffman K., Graf W., Sjödén P. O., Haglund U., Svensson C., Enander L. K., Linné T., Sellström H. Randomized comparison between chemotherapy plus best supportive care with best supportive care in advanced gastric cancer. Ann Oncol. 1997 Feb;8(2):163–168. doi: 10.1023/a:1008243606668. [DOI] [PubMed] [Google Scholar]
  9. Kelsen D., Atiq O. T., Saltz L., Niedzwiecki D., Ginn D., Chapman D., Heelan R., Lightdale C., Vinciguerra V., Brennan M. FAMTX versus etoposide, doxorubicin, and cisplatin: a random assignment trial in gastric cancer. J Clin Oncol. 1992 Apr;10(4):541–548. doi: 10.1200/JCO.1992.10.4.541. [DOI] [PubMed] [Google Scholar]
  10. Lokich J. J., Ahlgren J. D., Gullo J. J., Philips J. A., Fryer J. G. A prospective randomized comparison of continuous infusion fluorouracil with a conventional bolus schedule in metastatic colorectal carcinoma: a Mid-Atlantic Oncology Program Study. J Clin Oncol. 1989 Apr;7(4):425–432. doi: 10.1200/JCO.1989.7.4.425. [DOI] [PubMed] [Google Scholar]
  11. Machover D., Goldschmidt E., Chollet P., Metzger G., Zittoun J., Marquet J., Vandenbulcke J. M., Misset J. L., Schwarzenberg L., Fourtillan J. B. Treatment of advanced colorectal and gastric adenocarcinomas with 5-fluorouracil and high-dose folinic acid. J Clin Oncol. 1986 May;4(5):685–696. doi: 10.1200/JCO.1986.4.5.685. [DOI] [PubMed] [Google Scholar]
  12. Melcher A. A., Mort D., Maughan T. S. Epirubicin, cisplatin and continuous infusion 5-fluorouracil (ECF) as neoadjuvant chemotherapy in gastro-oesophageal cancer. Br J Cancer. 1996 Nov;74(10):1651–1654. doi: 10.1038/bjc.1996.604. [DOI] [PMC free article] [PubMed] [Google Scholar]
  13. Miller A. B., Hoogstraten B., Staquet M., Winkler A. Reporting results of cancer treatment. Cancer. 1981 Jan 1;47(1):207–214. doi: 10.1002/1097-0142(19810101)47:1<207::aid-cncr2820470134>3.0.co;2-6. [DOI] [PubMed] [Google Scholar]
  14. Murad A. M., Santiago F. F., Petroianu A., Rocha P. R., Rodrigues M. A., Rausch M. Modified therapy with 5-fluorouracil, doxorubicin, and methotrexate in advanced gastric cancer. Cancer. 1993 Jul 1;72(1):37–41. doi: 10.1002/1097-0142(19930701)72:1<37::aid-cncr2820720109>3.0.co;2-p. [DOI] [PubMed] [Google Scholar]
  15. Plukker J. T., Mulder N. H., Sleijfer D. T., Grond J., Verschueren R. C. Chemotherapy and surgery for locally advanced cancer of the cardia and fundus: phase II study with methotrexate and 5-fluorouracil. Br J Surg. 1991 Aug;78(8):955–958. doi: 10.1002/bjs.1800780820. [DOI] [PubMed] [Google Scholar]
  16. Plukker J. T., Sleijfer D. T., Verschueren R. C., Van der Graaf W. T., Mulder N. H. Neo-adjuvant chemotherapy with carboplatin, 4-epiadriamycin and teniposide (CET) in locally advanced cancer of the cardia and the lower oesophagus: a phase II study. Anticancer Res. 1995 Sep-Oct;15(5B):2357–2361. [PubMed] [Google Scholar]
  17. Preusser P., Wilke H., Achterrath W., Fink U., Lenaz L., Heinicke A., Meyer J., Meyer H. J., Buente H. Phase II study with the combination etoposide, doxorubicin, and cisplatin in advanced measurable gastric cancer. J Clin Oncol. 1989 Sep;7(9):1310–1317. doi: 10.1200/JCO.1989.7.9.1310. [DOI] [PubMed] [Google Scholar]
  18. Pyrhönen S., Kuitunen T., Nyandoto P., Kouri M. Randomised comparison of fluorouracil, epidoxorubicin and methotrexate (FEMTX) plus supportive care with supportive care alone in patients with non-resectable gastric cancer. Br J Cancer. 1995 Mar;71(3):587–591. doi: 10.1038/bjc.1995.114. [DOI] [PMC free article] [PubMed] [Google Scholar]
  19. Rougier P., Mahjoubi M., Lasser P., Ducreux M., Oliveira J., Ychou M., Pignon J. P., Elias D., Bellefqih S., Bognel C. Neoadjuvant chemotherapy in locally advanced gastric carcinoma--a phase II trial with combined continuous intravenous 5-fluorouracil and bolus cisplatinum. Eur J Cancer. 1994;30A(9):1269–1275. doi: 10.1016/0959-8049(94)90171-6. [DOI] [PubMed] [Google Scholar]
  20. Webb A., Cunningham D., Scarffe J. H., Harper P., Norman A., Joffe J. K., Hughes M., Mansi J., Findlay M., Hill A. Randomized trial comparing epirubicin, cisplatin, and fluorouracil versus fluorouracil, doxorubicin, and methotrexate in advanced esophagogastric cancer. J Clin Oncol. 1997 Jan;15(1):261–267. doi: 10.1200/JCO.1997.15.1.261. [DOI] [PubMed] [Google Scholar]
  21. Wilke H., Preusser P., Fink U., Gunzer U., Meyer H. J., Meyer J., Siewert J. R., Achterrath W., Lenaz L., Knipp H. Preoperative chemotherapy in locally advanced and nonresectable gastric cancer: a phase II study with etoposide, doxorubicin, and cisplatin. J Clin Oncol. 1989 Sep;7(9):1318–1326. doi: 10.1200/JCO.1989.7.9.1318. [DOI] [PubMed] [Google Scholar]
  22. Wils J. A., Klein H. O., Wagener D. J., Bleiberg H., Reis H., Korsten F., Conroy T., Fickers M., Leyvraz S., Buyse M. Sequential high-dose methotrexate and fluorouracil combined with doxorubicin--a step ahead in the treatment of advanced gastric cancer: a trial of the European Organization for Research and Treatment of Cancer Gastrointestinal Tract Cooperative Group. J Clin Oncol. 1991 May;9(5):827–831. doi: 10.1200/JCO.1991.9.5.827. [DOI] [PubMed] [Google Scholar]

Articles from British Journal of Cancer are provided here courtesy of Cancer Research UK

RESOURCES